U.S. HMC SERIES FUND LP - SERIES VIII records an exempt offering totaling $13,250,000, with $100,000 sold and eight investors listed. The figures give investors the fund’s stated fundraising scale, reported amount sold, participation count and $15,000 allocation for organizational and operating expenses.

Key Highlights

  • The fund lists $15,000 for organizational and operating expenses.
  • The offering record identifies eight investors.
  • Lind Global Fund III LP is reported with 5.65% ownership of Dare Bioscience, representing 1,094,890 common shares.

U.S. HMC SERIES FUND LP - SERIES VIII records an exempt offering totaling $13,250,000, with $100,000 shown as sold. The fund identifies itself as a Delaware Limited Liability company and a Venture Capital pooled Investment fund.

$13.25M Offering and Fund Structure

Eight investors are identified, while $15,000 is allocated to cover organizational and operating expenses. George G. Chen is identified as managing member for U.S. HMC SERIES FUND LP - SERIES VIII, with the record dated 1 September 2026. The record includes a decline-to-disclose entry and identifies the offering under exemptions marked 06b, 3C and 3C.1. A separate ownership record names Lind Global Fund III LP as reporting 5.65% ownership of Dare Bioscience, Inc (NASDAQ: DARE). consisting of 1,094,890 shares of common stock (1.09 million), 1,094,890 Series A Warrants and 1,094,890 Series B Warrants.